Articles

Poll

Podcasts

Slideshows

Videos

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

FDA prioritizes centanafadine's review for ADHD treatment, offering a novel first-in-class NDSRI option for adults, adolescents, and children.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

In 2025, psychiatry saw major FDA approvals, novel treatments, and pivotal clinical updates that are transforming care for depression, ADHD, schizophrenia, and anxiety.

​​Psychiatry in 2025: Year in Review

Otsuka Pharmaceuticals seeks FDA approval for centanafadine, a novel ADHD treatment, showing significant efficacy in pivotal clinical trials.

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

5 Psychiatry Headlines You Missed in September 2025

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link

Both ACOG and AAP have released statements disagreeing with the FDA label change for acetaminophen to reflect autism risk in children if used during pregnancy.

ACOG, AAP Respond to White House Autism Announcements on Acetaminophen, Leucovorin

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.


Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk

In a study, ADHD treatments were linked to reduced suicidal behavior, substance misuse, transport accidents, and criminality, but not accidental injuries.


ADHD Drugs Reduce Risk of Suicidal Behavior, Criminality, and More

Axsome’s phase 3 trial shows solriamfetol significantly improves ADHD symptoms, with a 45% mean reduction in AISRS scores and onset as early as week 1.


Solriamfetol Significantly Reduces ADHD Symptoms in Axsome’s Phase 3 Trial

ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.